占位病变手术引发诉讼之争:患方误解还是医方误治(附权威解读)?

2015-09-14 黄伟青 宋儒亮 岑钧华 等 中国医学论坛报

作者: 广东省医学会医事法学分会 黄伟青 宋儒亮 岑钧华 赵凯 赖永洪 李强 王文倩 刘芳 病例简介 2001年7月起,患者餐后出现腹痛、呕吐、持续性胀痛、高热、全身皮肤发黄、眼黄、尿黄等症状。 2002年1月22日,患者急诊入A医院治疗。 2002年2月5日,患者行肠镜检查,病理诊断:腺瘤性息肉伴轻度不典型性增生。经治疗好转后出院。 2002年2月26日,患者入B医院,磁共振(MR

作者: 广东省医学会医事法学分会 黄伟青 宋儒亮 岑钧华 赵凯 赖永洪 李强 王文倩 刘芳

病例简介

2001年7月起,患者餐后出现腹痛、呕吐、持续性胀痛、高热、全身皮肤发黄、眼黄、尿黄等症状。

2002年1月22日,患者急诊入A医院治疗。

2002年2月5日,患者行肠镜检查,病理诊断:腺瘤性息肉伴轻度不典型性增生。经治疗好转后出院。

2002年2月26日,患者入B医院,磁共振(MR)检查报告显示:胆总管出口结石(1.5cm),并肝内外胆道扩张;胆囊颈小结石。

2002年3月4日,患者再次入A医院。经超声波、计算机体层摄影(CT)等检查后考虑为胆管癌。

2002年3月9日、11日,患者家属签署《麻醉同意书》和《手术同意书》。手术同意书中,术前诊断中无“胰头占位性病变”;拟行手术方式为“胆囊切除、胆总管探查、胆肠吻合术,备胰十二指肠切除术”;可能的并发症及危险告知包括“若术中诊断为胰十二指肠占位,需行胰十二指肠切除术”。手术顺利取出胆总管结石,切除胰十二指肠等。手术记录记载:胆总管胰腺段触及一(1×1)cm大小占位性病变,质硬,胰头呈浸润性炎症改变;探查胆总管胰腺段见管腔呈增生性闭塞,决定行胰十二指肠切除术。病理检查报告单记载:胆总管壁纤维增生;黏膜上皮增生;慢性炎细胞浸润;胰腺间质有灶性炎细胞浸润;未见肿瘤。

2002年4月6日,患者出院。出院诊断为:梗阻性黄疸;继发性胆总管结石;慢性胰腺炎并胆总管胰腺段纤维增生;慢性胃炎;直肠癌术后。

最终患者以A医院误诊构成医疗事故为由向一审法院提起了诉讼。

一审各方主张及判决

原告(患者)意见

决认为A医院误诊构成医疗事故,提请进行医疗事故技术鉴定,并要求被告承担相应的赔偿责任。

医疗事故技术鉴定

某市医学会医疗事故鉴定书的分析意见认为:患者反复腹痛、眼黄、尿黄10个月,行各种检查后怀疑为胆总管下段阻塞、胆管癌待排除,故具有手术明确指征;术中发现胆总管下段闭塞,不排除癌症可能,行胰十二指肠切除术理由充分;手术操作符合常规,围手术期处理得当,无违规操作;术后患者康复顺利,未出现并发症,创口Ⅰ期愈合。

经讨论合议认为:医方与患者家属在术前、术中存在沟通不足问题,但本案例不属于医疗事故。

一审法院判决

据病历记录,A医院基于患者症状以及各项检查结果,认为患者胆总管下段阻塞,怀疑而非确定患者罹患胆管癌。A医院在患者具有合乎医疗规范的手术指征情况下决定实施手术,而非如患者所述,是因为认定患者罹患胆管癌而决定实施手术。

患者首次入A医院治疗的病理检查显示患者结肠息肉为轻度不典型性增生,加上患者具有直肠癌病史,因此A医院考虑患者可能患胆管癌并非轻率观点。

手术记录显示胰头部硬结位置较深,是否恶性须经病理检验。如该结节为恶性,穿刺会造成扩散,这具备相关医学理论支持,因此A医院当时决定实施胰十二指肠切除术是负责任的医疗行为。故对某市医学会作出的《医疗事故技术鉴定书》予以采信。患者诉讼请求不符合《中华人民共和国民法通则》第106条第2款之规定。

一审法院判决:驳回患者诉讼请求;患者负担本案3500元鉴定费与100元受理费。

二审各方主张及判决

一审判决后,原告不服,向二审法院提起上诉。上诉人(患者)

A医院在术前诊断患者为胰头占位性病变缺乏依据,患者在B医院的MR检查中诊断为胆总管结石,并无胰头病变。

手术同意书中,术前诊断中亦无胰头占位性病变,A医院并未向患者讲明要做胰十二指肠切除术,其配偶签署手术同意书时亦无该项,故A医院侵犯了患方知情权。

术后病理检查结果证实,患者无胰头部癌变、胰腺炎或胰腺纤维增生。故A医院误诊导致手术错误,将患者部分器官切除,对患者身体造成严重损害。据《医疗事故处理条例》有关规定,A医院应承担损害赔偿责任。

据此请求:撤销原审判决;依法改判。

被上诉人(A医院)

不同意患者上诉请求,同意原审判决。

A医院对患者的诊治符合医疗常规,为患者做胰十二指肠切除术正确,是对患者负责任的医疗行为。请求二审法院驳回患者上诉请求。

二审法院判决

本案争议焦点在于A医院诊疗护理是否存在过失及是否已尽到告知说明义务。

诊断方面

患者举出B医院MR检查结果,以证明其术前并无占位性病变,但未证明在治疗期间曾向A医院出示此检查结果,使A医院在术前知晓这一结果。

A医院诊断患者为胆总管胰头占位性病变,符合医学规范、常规。虽术后病理结果未见肿瘤,但并不能据此认为A医院诊断存在过失,因为“占位”并非专指恶性肿瘤,也可以是良性病变,包括良性增生及炎性包块。

治疗方面

文献记载,胰头占位的性质有时在术前、术中均难以确定。

其他部位的肿物通常可先取少量组织采用术中快速冰冻切片确定其性质,再决定手术方式。胰头部比较特殊,若行术中快速冰冻切片,结果不一定准确且可能带来较严重副损伤,故A医院直接选择胰十二指肠切除术不违反诊疗常规,亦不能以术后病理未发现恶性肿瘤为由认为A医院决策错误。

医学具有很强未知性、探索性和经验性,所采用的诊疗方法难免具有一定程度侵入性和损害性。

A医院根据患者病史、症状、体征和影像学检查结果,在高度怀疑患者胰头部位占位结节为恶性病变情况下,为最大程度避免肿瘤遗漏和解除症状而实施手术,指征明确、依据充分,虽造成患者器官损伤,但“两害相权取其轻,两利相权取其重”是面临两难问题时的理智选择。

告知说明义务方面

虽A医院在手术同意书中已说明“若术中诊断为胰十二指肠占位,需行胰十二指肠切除术”,但术前诊断中未列出胰头占位性病变一项,亦未向患方说明“占位”的复杂含义――并非专指恶性肿瘤,也包括良性肿瘤、炎性包块等,导致患方误以为术中确诊为癌变而行胰十二指肠切除术。胰十二指肠切除术手术范围广、切除器官多、手术风险大,A医院应向患者重点说明备胰十二指肠切除术的理由、术中可能影响手术决定的不同情况以及该手术风险和影响,包括即使术前及术中均高度怀疑癌变,但术后病理结果却为良性病变的可能性。

然而,手术同意书内容显然未达“充分告知”的要求。A医院亦未举证证明在术中及时将探查情况告知患者家属,以便家属作出知情决定,故认为A医院未尽告知说明义务,侵犯了患者的知情权和选择权。

某市医学会医疗事故鉴定程序合法,分析意见与本院所查明的事实相符,本院予以采信。患者在二审程序中要求重新鉴定,但在一审程序中,其明确表示不申请重新鉴定,故对其在二审程序中申请重新鉴定,本院不予准许。

由于A医院在告知说明方面的过失,使患者失去了做出知情决定的机会,降低了避免进行胰十二指肠切除术的可能性,增加了患者经济负担与精神痛苦。

但A医院在诊疗方面并无过失,患者术后恢复良好,术中切除部分器官对患者日常生活实际影响不大,且术后病理结果也为其明确了诊断,排除了肿瘤。

若将医疗风险所致后果过多归咎于医疗机构,会打击医方积极性,让医生在面对医疗风险时选择保护自身利益而非对疾病最适当的治疗策略,也会限制新技术、新疗法在临床医学中的运用。

综上所述,患者上诉请求部分成立,本院予以支持。A医院于本判决生效之日起五日内,一次性赔偿患者15000元。一、二审案件受理费各100元,均由A医院负担。医疗事故鉴定费由患者负担。

各方意见

医方代表

岑钧华[广州医科大学附属第一医院(广附一广附一))肝胆外科主任医师]、黄伟青(广附一医务科科长一医务科科长、、主任医师主任医师)、)赵凯(广附一医务科主管广附一医务科主管))

从事外科临床须严格把握手术适应证。要从搜集病史、体格检查、血生化和特殊检查(尤其是影像检查)中,得到尽可能明确的诊断,具备手术适应证再制定手术方案。本案例中术前诊断不够严谨:胆总管胰头段占位性病变的诊断只是根据超声和计算机体层摄影(CT),且与外院的磁共振(MR)结果有出入。该情况下更须慎重判断是否存在肿瘤,因为这牵涉到手术的复杂程度、患者的创伤大小以及是否过度医疗。可再行磁共振胰胆管造影(MRCP)查看胆管阻塞程度;也可再行超声内镜,甚至通过内镜作胰头占位的穿刺活检;还可行正电子发射CT(PET/CT)确认胰头占位是否存在及其性质。这些可为术前诊断提供更充分证据,从而帮助制定更完善的手术方案。

手术同意书显示患方未达充分告知说明的要求,使患者家属在没有充分了解病情的情况下作出选择。

律师代表

李强律师李强律师、、刘芳实习律师医疗机构与医务人员无一不知告知说明义务,但是由此引发的纠纷却不止。医方须注意调整的包括:①医学临床学习中,法律风险教育仍有缺失,统编教材、自编教材、临床诊疗规范、专业论著等均少见系统论述,这在今后的教材改版中必须补上;②告知说明过于简单和程式化,目前不少医疗机构都只是提供格式化的术前谈话/风险告知说明签字同意书,忽略了个体差异;③告知说明是双向的行为和活动,仅医方向患方告知是不够的,需医患双向的交流沟通;④医方对不可预见性因素的防范处置水平有待提高,例如就术中突发的情况与患方的沟通。

法官代表

法官官健健((广东省中级人民法院级人民法院))患者术前诊断为肝内外胆管结石、胰头占位性病变,可疑胆管癌。“占位”是临床上较为常用的诊断术语,往往指在人体内脏中发现的异常存在、原因不明、性质不清、占据一定空间的物体,有待进一步查明原因、明确性质。“占位”的性质通常要通过病理检查而最终得到明确。有些“占位”可以通过术前穿刺取活检做病理明确诊断,有些需要在术中取活检做快速冰冻切片明确性质。但胰头部位比较特殊,即便在术中取活检做冰冻切片,其结果也可能不够准确,而且副损伤较大,往往得不偿失。故临床上比较通行的做法是,在术中探查明确胰头占位、不能排除恶性肿瘤的情况下,直接做胰十二指肠根治手术。本案中,医方采用的正是这一做法,经医学会鉴定,手术本身并不存在过失。但医方在术前应将这一情况向患者充分说明。然而,在手术同意书中,医院在术前诊断一项中并未写明“胰头占位性病变、可疑胆管癌”,仅在手术方式一栏中写“备胰十二指肠切除术”及手术风险一栏中写“若术中诊断为胰十二指肠占位,需行胰十二指肠切除术”,并且未向患方解释说明“占位”这一专业术语,让患方误解为确诊为癌症,从而同意手术。医方还应向患方说明胰十二指肠切除术的手术风险,切除范围,对住院时间、治疗费用、日后生活的影响,以及切除后病理检查未发现癌的可能性。显然,医方是否告知上述内容将决定患者是否能在充分知情的基础上行使选择权。故医方侵犯了患者的知情同意权。

精彩点评与启示

宋儒亮:医学上做得对、法律上守得对,才算依法行医

广东省医学会医事法学分会法治广东研究中心宋儒亮主任

医方为何要对患者进行说明告知?

这个问题的答案既清楚简单,又模糊复杂。一方面,该问题已得到伦理、人文、法律等各方面的清楚解释和成文规定,临床上只管执行即可。另一方面,医务工作者却又时常困惑:全面、深入地说明告知究竟对患者治疗本身有何益处?

困惑常常通过具有争议性的案件来体现,其引导可通过多角度进行,而最一针见血的就是:若未事先进行说明告知,而诊疗中出现问题,又当如何处理?显然,之所以要求医方依法行医,就是承认了以下这一无奈的事实:专业性很强的医学活动也会遇到情况不明、无法保证治疗效果的疾病,与其事后难以给患方一个合理的解释和交代,不如事先全面、如实地说明告知。以医方事先的“说明”回应患方事后可能的“说法”,医学上无法确定的却先从法律上确定,就是面对无奈状况的无奈选择。权衡利弊、维护医患双方权益的最大公约数就是法律,最大共识就是法治之道。遵守法律、以法说事,是无奈选择的底线。若疾病情况清晰、可保证治疗效果,说明告知就不见得如此实际而重要了。

因此,说明告知不只是医方的义务,也是对医方的保护。面对疾病,医方须追问自己:能否理清该疾病的来龙去脉,处理能否有效恰当?答案若是存疑的、否定的,就要事先进行如实、清楚、全面、深入的说明告知。若患方对此能够理解和认同,之后的沟通就能愉快、顺利、有序地进行。

医方为何要按法对患者进行说明告知?

疾病诊疗护理活动涉及各项复杂事宜、内容和环节等。说明告知并不是治疗方法,说明告知之后,疾病既不会自然好转,责任也不一定能免。在现实中,未说明告知也不一定承担了责任。

那么该如何分辨、拿捏说明告知的内容与程度?回答这个问题有三类不同的标准:情、理和法。正确的做法必须守住最明确直接的底线,即“法”。除了依法进行之外,没有万全之策。

医生按法进行说明告知的边界在哪儿?

当医方行为正确,但患方不接受、不满意时,就须从第三方角度,找到共同的底线,才具有评价和指导意义。按法说明告知就是这个底线,就是医患双方沟通的边界。

按法进行说明告知也是最有情、有理之举。患者千差万别,理与情的接受能力往往大相径庭,对诊疗的评价也五花八门。诚然,法之上、之外还有情、理,依情行医、依理行医或许在某些方面优于依法行医,却定有一难解之问:讲情讲理,难免挂一漏万、难让人人认可、难为第三方把握。

除了“法、法制、法治”之外,再无让各方满意的共同、共识方式。依法行医并不完美,也并不为人人所理解、认可、接受和遵守,但却是平衡行医之底线。

法律上的“正确”有别于医学上的“正确”。从法律角度,医方对患者的说明告知事项大致可分为三大类。第一类是法律法规明确规定的“有名事项类”,包括但不限于:①病情;②医疗措施;③实施手术、特殊检查和特殊治疗;④医疗风险;⑤替代医疗方案;⑥实验性临床医疗。第二类是法律法规明确的“谨慎注意事项类”,包括但不限于:①及时解答患者咨询;②不宜向患者说明的,应当向患者的近亲属说明并取得书面同意;③注意避免对患者产生不利后果。第三类是法律法规明确规定的“开放事项类”:随着新法规出现,又存在新增说明告知事项的可能,也就是说,在沟通问题上,服务好患者并没有终点。综上所述,只要医方能充分告知说明以上事项,就是依法沟通、依法行医了。

总之,医学与法律各有领域、各有主张,彼此各自实现、有机结合、完全统一,才算是依法行医。就本案而言,医学方面医方并无过错,但患方并不认可,且通过行使法律赋予的权利,让其主张得到了法律肯定。这揭示了如下道理:医学方面行为正确,但法律上防护不恰当,并不是成功的诊疗护理。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-07-25 1e0c3e91m63(暂无匿称)

    医生要学习的还很多

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-01-11 medsic

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-01-11 medsic

    支持

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-01-11 medsic

    不错,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-01-11 medsic

    支持楼上,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-01-11 medsic

    感谢分享~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2016-04-13 wjcjjian
  8. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2015-10-08 hlycom3356

    这篇文章写得很好

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=94690, encodeId=1369946907e, content=医生要学习的还很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec7f1928456, createdName=1e0c3e91m63(暂无匿称), createdTime=Mon Jul 25 22:52:00 CST 2016, time=2016-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55670, encodeId=5afa556e087, content=嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55671, encodeId=cf79556e1a5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55672, encodeId=b8bd556e2f7, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55673, encodeId=87ba556e34a, content=支持楼上,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55674, encodeId=5a76556e47c, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Mon Jan 11 12:41:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667050, encodeId=bc6d166e050d7, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Wed Apr 13 21:20:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38202, encodeId=9a3a382023b, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Oct 08 16:37:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568431, encodeId=73a2156843138, content=<a href='/topic/show?id=3b5c91852e0' target=_blank style='color:#2F92EE;'>#误解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91852, encryptionId=3b5c91852e0, topicName=误解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3eeb15379220, createdName=snf701212, createdTime=Wed Sep 16 14:20:00 CST 2015, time=2015-09-16, status=1, ipAttribution=)]
    2015-09-16 snf701212

相关资讯

AIM:溃疡性结肠炎(UC)患者选择手术治疗可改善生存

溃疡性结肠炎(UC)可用外科手术或药物进行治疗。患者往往要在长期免疫抑制剂治疗或全结肠切除术之间做出选择。但无论选择哪一种治疗方法,死亡率都是不确定的。该研究的目的是为了与药物治疗相比,确定晚期UC患者是否可以通过选择结肠切除治疗提高生存率。该回顾性配对队列研究的数据来自50个州的医疗补助受益人(2000年至2005年),医疗保险受益人(2006年到2011),和上述两种人群(2000年至2011

30小时10台手术 俩医生累趴

“多亏了两位好医生,否则我就没命了。”昨日,汉口聋哑人士朱汉军在出院前,给武汉市中心医院胃肠外科的两位医生送来感谢信,夫妻俩用手语道谢,感谢他们的救命之恩。52岁的朱汉军家住二七路附近,和妻子同是聋哑人,平时靠种菜为生,为人很热心。18日晚10时许,朱汉军发现有小偷企图进他家偷东西,发出尖叫声阻止,小偷吓得转头就跑,朱汉军紧追过去。在追逐过程中,他被对方连捅6刀,倒在血泊中。有老街坊发现他受了伤,

JAMA Oncol:乳腺导管原位癌真的有必要手术吗?

乳腺癌是全世界妇女的头号杀手,大约占所有妇女癌症的16%。乳腺癌可根据肿块大小和扩散情况而分为很多期。导管原位癌(DCIS),即0期乳腺癌,大约占了乳腺癌患者的20%。它的特征是肿块局限在一处,还未扩散到淋巴结。 在这种疾病发现之后,绝大多数妇女会接受手术治疗:要么是乳房肿瘤切除术,切除乳房中的肿块;要么是乳房切除术或双乳切除术,切除一侧或两侧乳房。然而,JAMA Oncology上最新发表的一

你来或者不来 我就在这里——医生的坚守

当夜幕降临,路边的灯火开始闪烁,许多人结束了一天的工作,踏上回家的路时,医生的夜班才刚刚开始;当你正在与家人围坐在一起,感受节日的喜庆时,医生还得留在医院,陪伴在患者的身旁;当你说累了,来一场说走就走的旅行时,医生可能还要为患者的下一台手术做准备。日复一日,年复一年,医生把所有的时间都给了患者,无论你来或者不来,他都在这里守候。 医院里的患者来了又走,一拨又一拨。患者看病时都注重自己

CUA 2015:看看香港怎样进行微创手术模拟训练

第十三届亚洲泌尿外科学会年会(UAA2015)暨第二十二届全国泌尿外科学术会议(CUA 2015)于2015年9月3-6日在中国上海召开。在全体大会上,来自香港的Chan Ning-hong医生介绍香港微创泌尿外科手术的模拟训练,真是涨姿势呀! 传统泌尿外科训练主要依靠“师傅带徒弟”或“学徒式。这种代教方式依靠于有经验的外科医生花费大量时间和资源来带教,而且带教需要在真实病人上演练。这种操作的训

JAMA Oncol:早期乳腺癌患者有必要接受手术及放射治疗吗?没必要!

据发表于JAMA Oncology的一项新的研究显示,手术和放疗并不适合女性早期乳腺癌的治疗。0期乳腺癌,即导管原位癌(DCIS),是非侵袭性乳腺癌中最常见的形式,占所有的乳腺癌病例的20%。当癌细胞局限于乳导管中而并尚未扩散到周围组织变可确诊DCIS,意味着癌细胞无法转移到乳腺外。诊断为DCIS后,部分女性患者可继续发